Plasma transforming growth factor α and amphiregulin protein levels in NCIC clinical trials group BR.21

Journal of Clinical Oncology

Volumn 28, Issue 36, 2010, Pages 5247-5256

  Addison, Christina L ^a   Ding, Keyue ^a   Zhao, Huijun ^a   Maître, Aurélie Le ^a   Goss, Glenwood D ^a   Seymour, Lesley ^a   Tsao, Ming Sound ^a   Shepherd, Frances A ^a   Bradbury, Penelope A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BIOLOGICAL MARKER; ERLOTINIB; LACTATE DEHYDROGENASE; PLACEBO; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL (TOPIC); ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SMOKING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; QUINAZOLINES; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 79951911113     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.0805     Document Type: Article

References (32)

1. Dutta PR, Maity A: Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254:165-177, 2007 (Pubitemid 47161103)
2. Ettinger DS: Clinical implications of EGFR expression in the development and progression of solid tumors: Focus on non-small cell lung cancer. Oncologist 11:358-373, 2006
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
4. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005 (Pubitemid 41058345)
5. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001 (Pubitemid 33674041)
6. Pesonen K, Viinikka L, Myllyla G, et al: Characterization of material with epidermal growth factor immunoreactivity in human serum and platelets. J Clin Endocrinol Metab 68:486-491, 1989 (Pubitemid 19052896)
7. MacNeil S, Dawson RA, Crocker G, et al: Extracellular calmodulin and its association with epidermal growth factor in normal human body fluids. J Endocrinol 118:501-509, 1988
8. Normanno N, Bianco C, Strizzi L, et al: The ErbB receptors and their ligands in cancer: An overview. Curr Drug Targets 6:243-257, 2005 (Pubitemid 40667793)
9. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007 (Pubitemid 47325606)
10. Kakiuchi S, Daigo Y, Ishikawa N, et al: Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 13:3029-3043, 2004 (Pubitemid 40045258)
11. Masago K, Fujita S, Hatachi Y, et al: Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci 99:2295-2301, 2008
12. Ishikawa N, Daigo Y, Takano A, et al: Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 65:9176-9184, 2005 (Pubitemid 41507981)
13. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184, 2005 (Pubitemid 41258223)
14. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
15. Zhu CQ, da Cunha Santos G, Ding K, et al: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 26:4268-4275, 2008
16. Tsao MS, Aviel-Ronen S, Ding K, et al: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25:5240-5247, 2007 (Pubitemid 350232256)
17. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
18. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
19. French AR, Tadaki DK, Niyogi SK, et al: Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J Biol Chem 270:4334-4340, 1995
20. Roepstorff K, Grandal MV, Henriksen L, et al: Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 10:1115-1127, 2009
21. Willmarth NE, Baillo A, Dziubinski ML, et al: Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal 21:212-219, 2009
22. Berasain C, Castillo J, Perugorria MJ, et al: Amphiregulin: A new growth factor in hepatocarcinogenesis. Cancer Lett 254:30-41, 2007 (Pubitemid 47058802)
23. Castillo J, Erroba E, Perugorria MJ, et al: Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 66:6129-6138, 2006
24. Billings SD, Southall MD, Li T, et al: Amphiregulin overexpression results in rapidly growing keratinocytic tumors: An in vivo xenograft model of keratoacanthoma. Am J Pathol 163:2451-2458, 2003 (Pubitemid 37466486)
25. Willmarth NE, Ethier SP: Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem 281:37728-37737, 2006 (Pubitemid 46042076)
26. Gschwind A, Hart S, Fischer OM, et al: TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. Embo J 22:2411-2421, 2003 (Pubitemid 36604980)
27. Eckstein N, Servan K, Girard L, et al: Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 283:739-750, 2008
28. Britton DJ, Hutcheson IR, Knowlden JM, et al: Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96:131-146, 2006
29. Fontanini G, De Laurentiis M, Vignati S, et al: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241-249, 1998 (Pubitemid 28062903)
30. Tateishi M, Ishida T, Mitsudomi T, et al: Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 50:7077-7080, 1990 (Pubitemid 20361116)
31. Mutsaers AJ, Francia G, Man S, et al: Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res 15:2397-2405, 2009
32. Jacobs B, De Roock W, Piessevaux H, et al: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27:5068-5074, 2009